SMMRT™ Solutions for Better Outcomes
Building a Healthy World Through Microbial Biotechnology
Biofilm Management with Groundbreaking Technology
Primal Therapies' innovative technology enables its partners to pioneer new treatments for microbially-driven infections and inflammatory diseases. We offer patented functional ingredients and small molecule new drugs for biofilm, infection, and microbiome control.
With solutions that combine microbiology and molecular nutrition, our technology can impact multiple industries.
ANTIMICROBIAL RESISTANCE (AMR)
Microbial biofilms are responsible for 80% of human infections, a substantial number of which are now demonstrating antimicrobial resistance (AMR). This phenomenon is exacerbating challenges in contexts such as nosocomial infections and food-borne pathogens. The economic impact of AMR is substantial, estimated at an annual $500 billion. Given this severity, the World Health Organization has formally identified AMR as one of the top 10 global public health threats facing humanity. Foresight suggests that by 2040, bacterial infections will emerge as the predominant cause of mortality globally.
Therefore, the development of novel methodologies for inhibiting AMR infectious agents represents a critical area of ongoing research.
DISINFECTION
Hospital-acquired infections (HAIs) present a critical challenge within American healthcare. The CDC reports these infections account for an estimated 1.7 million cases and 99,000 deaths annually in U.S. hospitals, translating to a staggering $45 billion USD in costs.
The impact extends to senior living, where infection-related complications in residents with chronic conditions lead to an average annual expenditure of $31,000 per individual, creating an immense financial burden on Medicare.
This pervasive issue highlights an increasing imperative for non-toxic and more efficacious disinfection solutions tailored for hospitals, educational institutions, senior care facilities, and beyond.
MICROBIOME MODULATION
Mounting evidence reveals the profound influence of the microbiome on the onset and severity of numerous chronic diseases. Traditional interventions, often involving fecal transplants or extensive antiseptic/antibiotic use, carry inherent risks. Consequently, research is increasingly focusing on novel strategies for modulating bacterial composition.
A new wave of innovative microbiome modulation approaches is now emerging in the market and under development.
Get SMMRT™
™Selective Microbial Metabolism Regulation Technology (SMMRT)™ is a novel platform technology that develops patented small molecule agents targeting metabolic receptors and enzymes in bacteria, viruses, and fungi.
